Win Advisors Inc. Invests $1.02 Million in Biogen Inc. (NASDAQ:BIIB)

Win Advisors Inc. bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,686 shares of the biotechnology company's stock, valued at approximately $1,022,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in Biogen by 13,574.7% in the 4th quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company's stock valued at $407,919,000 after buying an additional 2,648,024 shares during the period. International Assets Investment Management LLC lifted its position in Biogen by 19,722.9% during the 3rd quarter. International Assets Investment Management LLC now owns 358,992 shares of the biotechnology company's stock worth $695,870,000 after acquiring an additional 357,181 shares in the last quarter. Mizuho Securities USA LLC lifted its position in Biogen by 2,715.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 316,000 shares of the biotechnology company's stock worth $61,253,000 after acquiring an additional 304,778 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Biogen during the 3rd quarter worth approximately $55,826,000. Finally, State Street Corp raised its position in shares of Biogen by 3.5% in the 3rd quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company's stock valued at $1,423,747,000 after purchasing an additional 248,942 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Stock Performance

NASDAQ:BIIB traded up $3.04 during mid-day trading on Wednesday, hitting $145.53. 1,173,200 shares of the company's stock traded hands, compared to its average volume of 1,265,540. The firm has a 50 day moving average of $150.16 and a two-hundred day moving average of $177.18. Biogen Inc. has a 12 month low of $139.71 and a 12 month high of $246.44. The firm has a market capitalization of $21.21 billion, a price-to-earnings ratio of 13.15, a price-to-earnings-growth ratio of 1.66 and a beta of -0.08. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Mizuho cut their target price on Biogen from $251.00 to $207.00 and set an "outperform" rating on the stock in a research report on Thursday, November 21st. Stifel Nicolaus downgraded Biogen from a "buy" rating to a "hold" rating and set a $175.00 price target for the company. in a report on Monday, December 16th. HC Wainwright reiterated a "buy" rating and issued a $300.00 price target on shares of Biogen in a report on Thursday, October 31st. Truist Financial lowered their price objective on Biogen from $302.00 to $220.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group downgraded Biogen from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $250.00 to $180.00 in a research note on Monday, December 9th. Sixteen research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $228.80.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.